550 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B Sell
Article Searches
3 Big Pharma Stocks to Add to Your Portfolio This April http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-ZC-FT-368171 Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-ZC-FT-367176 Mar 29, 2019 - AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
Lilly (LLY) Signs New Immunology Deal With Private Biotech http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-ZC-FT-365638 Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Biogen’s Big Bet in Alzheimer’s Disease Is a Bust https://www.fool.com/investing/2019/03/21/biogens-big-bet-in-alzheimers-disease-is-a-bust.aspx?source=iedfolrf0000001 Mar 21, 2019 - The big biotech's pivot from multiple sclerosis to Alzheimer's disease was dealt a decisive blow today.
Alkermes Focuses on Pipeline, Depends on Partners for Funds http://www.zacks.com/stock/news/362777/alkermes-focuses-on-pipeline-depends-on-partners-for-funds?cid=CS-ZC-FT-362777 Mar 21, 2019 - Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-ZC-FT-359294 Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Eli Lilly (LLY) Flat As Market Gains: What You Should Know http://www.zacks.com/stock/news/359060/eli-lilly-lly-flat-as-market-gains-what-you-should-know?cid=CS-ZC-FT-359060 Mar 12, 2019 - Eli Lilly (LLY) closed at $123.50 in the latest trading session, marking no change from the prior day.
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat http://www.zacks.com/stock/news/358423/celldex-cldx-q4-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-358423 Mar 08, 2019 - Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache http://www.zacks.com/stock/news/357965/lillys-emgality-gets-fda-priority-review-for-cluster-headache?cid=CS-ZC-FT-357965 Mar 06, 2019 - Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.

Pages: 1234567...55

<Page 2>